Last update Dec. 19, 2013


Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a μ-opioid receptor antagonist that accelerates intestinal transit. Prescribed after intestinal surgery procedures.

Since oral absorption and plasma levels are very low secretion into breast milk is thought to be minimal.


We do not have alternatives for Alvimopan.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Alvimopan belongs to this group or family:


Main tradenames from several countries containing Alvimopan in its composition:


Variable Value Unit
Oral Bioavail. 6 %
Molecular weight 460 daltons
Protein Binding 80 %
Tmax 2 hours
18 hours


  1. Hussar DA. New drugs 09, part 1. Plast Surg Nurs. 2009 Abstract
  2. Alvimopan Data Sheet ( 2009 Full text (in our servers)
  3. Foss JF, Fisher DM, Schmith VD. Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials. Clin Pharmacol Ther. 2008 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM